(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: a novel class of potent MSK-1-inhibitors |
| |
| Authors: | Bamford Mark J Alberti Michael J Bailey Nicholas Davies Susannah Dean David K Gaiba Alessandra Garland Stephen Harling John D Jung David K Panchal Terence A Parr Christopher A Steadman Jon G Takle Andrew K Townsend James T Wilson David M Witherington Jason |
| |
| Institution: | GlaxoSmithKline Pharmaceuticals, Neurology and GI Centre of Excellence for Drug Discovery, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK. Mark_J_Bamford@GSK.com |
| |
| Abstract: | A novel series of imidazo4,5-c]pyridines bearing a 1,2,5-oxadiazol-3-ylamine functionality has been developed. These are potent inhibitors of mitogen and stress-activated protein kinase-1. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
